merck - Search News

Merck 2025 Sales Forecast Underwhelms

Hosted on MSN · 2h

Merck’s Gardasil Halt Shows Blockbuster Shots’ Dilemma in China

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US pharmaceutical giant made the call earlier this week to halt shipments.

Business Insider · 10h

Merck Stock Loses 9% on Vaccine Shipment Halt to China

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The pharmaceutical

The Associated Press - Busines… · 1d

Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

Merck stock slides

Merck beats estimates on fourth-quarter on earnings—but stock slides pre-market on tepid 2025 guidance

Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its stock was down more than 8% in pre-market trading, largely because of weaker than expected 2025 guidance.

Seeking Alpha · 1d

Merck stock slides as 2025 earnings outlook misses estimates

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations with Keytruda sales.

Business Insider · 1d

MRK Earnings: Weak 2025 Guidance Mangles Merck Stock Today

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted

5hon MSN

Merck Is Suffering From a Classic Pharma Problem

Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.

Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

3h

Merck price target lowered to $112 from $118 at BofA

BofA lowered the firm’s price target on Merck (MRK) to $112 from $118 and keeps a Buy rating on the shares. Q4 results were “decent,” but 2025 ...

22h

Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

21h

Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential

Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

19hon MSN

These Stocks Are Moving the Most Today: Palantir, Alphabet, Tesla, Merck, PayPal, Super Micro, Spotify, Estée Lauder, and More

Palantir stock surges as artificial-intelligence gains drive an earnings and revenue beat, China begins an antitrust probe ...

StockStory.org on MSN1d

Merck’s (NYSE:MRK) Q4 Sales Top Estimates But Stock Drops

Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results , with sales up 6.8% year on year to $15.62 billion ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results